reports
Forward Pharma Announces Expected Delisting of its American Depositary...
Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American D...
Forward Pharma Announces the Decision of the Enlarged Board of Appeal ...
Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition for review (the “Petition”) of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding (“Opp...
Forward Pharma Announces the Decision of the Technical Board of Appeal...
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has dismissed Forward’s appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the “’355 patent”) following the oral hearing. The TBA made its decision after considering Forward’s appeal again...
Forward Pharma Reports Financial and Operational Results from the Year...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020 COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended December 31, 2019. Our research and development and general and administrative cos...
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing ...
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Paten...
Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due...
Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19 COPENHAGEN, Denmark, May 12, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to current precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Patent”). The new hearing date is February 2, 202...
Forward Pharma Reports Financial and Operational Results from the Year...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2019 COPENHAGEN, Denmark, April 24, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019. Our net loss for the year ended December 31, 2019 was $(4.2) million, or $(0.04) per share, versus a net loss of $(8.7) million, or $(0.09) per share for the year ended December 31, 2018. Our research and development and general ...
Forward Pharma A/S Announces Change in Ratio of American Depositary Sh...
Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from two ordinary shares per ADS to 14 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-7 reverse stock split of the ADSs....
Forward Pharma to Participate in the Fall Investor Summit in New York
Forward Pharma to Participate in the Fall Investor Summit in New York COPENHAGEN, Denmark, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Chief Executive Officer, Dr. Claus Bo Svendsen, will participate in the Fall Investor Summit investor conference () in New York, NY. Dr. Svendsen will present a corporate update on Tuesday, September 17, 2019 at 8:00 AM ET and will be available for one-on-one meetings. About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprie...
Forward Pharma A/S Announces Intention to Transfer its U.S. Public Lis...
Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This follows the development in the Company’s American Depositary Shares (“ADSs” or “shares”) price after the Settlement and License Agreement with Biogen, and the significant return of capital to its shareholders i...
Forward Pharma Reports Financial and Operational Results from the Year...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018 COPENHAGEN, Denmark, April 04, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. Our net loss for the year ended December 31, 2018 was $(8.7) million, or $(0.09) per diluted share, versus net income of $917.1 million, or $2.30 per diluted share for the year ended December 31, 2017. Our research, development, general and a...
Forward Pharma to Participate in the DKBIO2019 Life Science Investor C...
Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference COPENHAGEN, Denmark, March 27, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in ...
Forward Pharma Provides Update on the Decision of the Federal Circuit ...
Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference The U.S. Court of Appeals for the Federal Circuit has affirmed the decision of the Patent Trial and Appeal Board in the U.S. patent interference proceedingThe appeal of the European EP2801355 patent opposition continuesForward expects to reduce operating expenses to match the current situation COPENHAGEN, Denmark, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP) (“Forward” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Cir...
Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcar...
Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference COPENHAGEN, Denmark, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY. Dr. Svendsen will present a corporate update on Tuesday, October 2, 2018 at 11:30AM ET and will be available for one-on-one meetings. Investors and other interested parties may access a live audio webcast of Dr. Svendsen’s conference...
Forward Pharma Reports Financial and Operational Results from the Firs...
Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018 COPENHAGEN, Denmark, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We”, “Forward” or the “Company” and together with its subsidiaries, the “Group”), today reported consolidated financial results for the six-month period ended June 30, 2018. Net loss for the six-month period ended June 30, 2018 was $(5.3) million, or $(0.06) per diluted share, versus net income of $941.2 million, or $1.67 per diluted share for the six-month period ended June 30, 2017. “We are pleased to annou...
Forward Pharma to Participate in the LSX Nordic Congress
Forward Pharma to Participate in the LSX Nordic Congress COPENHAGEN, Denmark, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the LSX Nordic Congress being held August 29-30, 2018 in Stockholm, Sweden. Dr. Svendsen will present a corporate update on Thursday, August 30, 2018 at 15.15 CET and will be available for one-on-one meetings. A recording of the presentation will be made available through the Company’s website. About Forward Pharma: Forward Pharm...
QuickView: To the victor the spoils...but not quite yet
Forward Pharma has been designated the senior party in the US Patent Trial and Appeal Board (PTAB) interference proceedings between Forward's '871 patent application and Biogen's '514 patent, based on its earlier filing date. The average time to interference resolution is ~13 months (excluding appeals) and investors will see the legal arguments filed in July and September 2015. If Forward Pharma prevails, damages awarded could be significant.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.